Age groups | median age (range) | age p-value | CMV seropositivity % (n) | CMV p-value | male % (n) | sex p-value | N |
young adults (YA) | 29 (25–48) | YA-MA: 0.011 | 43 (3) | YA-MA: 0.062 | 29 (2) | YA-MA: 0.061 | 7 |
middle aged adults (MA) | 60 (55–62) | MA-OA: 0.002 | 62 (5) | MA-OA: 0.010 | 50 (4) | MA-OA: 0.067 | 8 |
older adults (OA) | 72 (65–77) | OA-YA: <0.0001 | 62 (10) | OA-YA: 0.065 | 62 (10) | OA-YA: 0.019 | 16 |
all | 65 (25–77) | 58 (18) | 52 (16) | 31 | |||
Vaccine response groups | median age (range) | age p-value | CMV seropositivity % (n) | CMV p-value | male % (n) | sex p-value | N |
low responders (LR) | 69 (39–76) | LR-HR: 0.068 | 65 (11) | LR-HR: 0.065 | 65 (11) | LR-HR: 0.210 | 17 |
high responders (HR) | 60 (25–77) | 50 (7) | 36 (5) | 14 |